Analysts Offer Insights on Healthcare Companies: AVEO Pharma (AVEO), Acelrx (ACRX) and Kala Pharmaceuticals Inc (KALA)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on AVEO Pharma (AVEO), Acelrx (ACRX) and Kala Pharmaceuticals Inc (KALA).

AVEO Pharma (AVEO)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Hold rating on AVEO Pharma, with a price target of $1. The company’s shares closed yesterday at $0.70, close to its 52-week low of $0.67.

Ramakanth wrote:

“We adjust our rating of AVEO to and lower our 12-month price target to $1.00 per share, down from $9.00. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.5% discount rate and 3% terminal growth rate. We derive an rNPV of $213M for the products and add in cash and cash equivalents of $20M to arrive at a 12-month price target of $1.03 per diluted share, which we round to $1.00.”

According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.7% and a 34.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.

Currently, the analyst consensus on AVEO Pharma is a Strong Buy with an average price target of $3.50.

See today’s analyst top recommended stocks >>

Acelrx (ACRX)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Acelrx today and set a price target of $9. The company’s shares closed yesterday at $2.46.

Arce noted:

“We project U.S. peak sales of $325M in 2026 for DSUVIA. For Zalviso, we project product launch in 1H20 (85% POS) with peak sales in 2027 of about $185M. We apply a 12.5% discount rate to both products.”

According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.5% and a 37.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acelrx with a $9.25 average price target, implying a 276.0% upside from current levels. In a report issued on January 29, Cantor Fitzgerald also maintained a Buy rating on the stock with a $9 price target.

Kala Pharmaceuticals Inc (KALA)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kala Pharmaceuticals Inc, with a price target of $15. The company’s shares closed yesterday at $5.53, close to its 52-week low of $4.03.

Selvaraju noted:

“Our 12-month price target is derived from a market value of the firm at $495M, which includes a discounted cash flow-based asset value of $570M for INVELTYS (100% probability of success) and KPI-121 0.25% (65% probability of success), with a 15% discount rate and 0.5% terminal growth rate, excluding $75M debt.”

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -14.5% and a 27.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Kala Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts